Skip to main content

Table 2 Description of liver dysfunction between non-severe and severe among included studies

From: A meta-analysis of the impact of COVID-19 on liver dysfunction

Study, year Setting Country Sample (non-severe/severe) Age (non-severe/severe) Chronic liver disease (non-severe/severe) ALT (non-severe/severe) AST (non-severe/severe) TBIL. (non-severe/severe) Female NOS
Chen guang
et al. [17], 2020a
Isolation ward China 10/11 52.0(42.8–56.0)/61.0 (56.5–66.0) NA 16.0 (13.3–21.8)/42.0 (32.5–50.0) 24.0(21.5–26.5)/47.0 (28.0–74.5) 7.8 (6.4–9.5)/8.8 (7.9–10.5) 1/3 7
Zheng et a. [18], 2020 Isolation ward China 131/30 40 (31–51)/57 (46.5–66) 4/0 19.3 (14.6–17.8)/23.9 (17.6–35.3) 23.4 (19.0–28.8)/31.6 (25.9–49.36) 10.7 (8.18–15.3)/12.7 (9.2–16.9) 65/16 7
Wan et al. [11], 2020 Isolation ward China 95/40 44(33–49)/56(52–73) 1/1 21.7(14.8–36.9)/26.6(14.5–33.3) 22.4(16.9–30.5)/33.6(25.7–44.2) 8.6(5.6–14)/9.8(7.8–15.6) 43/19 8
Zhang et al. [19], 2020b Isolation ward China 84/31 43.96 ± 14.84/64.58 ± 13.26 3/2 (Hepatitis B) 21.22 ± 12.67/37.87 ± 32.17 24.39 ± 9.79/38.87 ± 22.55 10.27 ± 4.26/14.12 ± 6.37 55/11 7
Guan et al. [20], 2020c Isolation ward China 926/173 45.0(34.0–57.0)/52.0 (40.0–65.0) 22/1 (Hepatitis B) 120/606 vs 38/135 112/615 vs 56/142 59/594 vs 17/128 386/73 8
Ji et al. [21], 2020 Isolation ward China 163/39 42.9 (32.6 -
51.8)/55.1 (43.7 -71.8)
42/34 (NAFLD)
5/2 (HBsAg)
82/163 vs 19/39 24/163 vs 10/39 13/163 vs 4/39 77/12 7
Cai et al. [8]. 2020d Isolation ward China 233/85 (A)
47/43 (B)
NA 78/60 (A)
28/41 (B)
41 (23–65)/67 (47–100) (A)
84 (42–136)/96 (63–159) (B)
34(27–45)/58(41–93) (A)
45(29–81)/80(56–145) (B)
19 (13–26)/22 (18–28) (A)
22 (15–41)/25 (19–32) (B)
NA 7
Li et al. [10], 2020e Isolation ward China 279/269 56 (44–66)/65 (54–72) 2/2 61/275 vs 64/266 64/275 vs 115/265 7/275 vs 17/266 153/116 7
  1. Data expressed by mean ± SD, median (IQR) or n/N. IQR = interquartile range. ALT: alanine aminotransferase (> 41 U/L). AST: aspartate aminotransferase (> 40 U/L). TBIL: total bilirubin (> 21 μmol/L). NAFLD: non-alcoholic fatty liver diseases. HBsAg: Hepatitis B virus surface antigen positivity
  2. aPatients based on AST > 40U/L
  3. bPatients based on ALT > 50U/L
  4. cPatients based on TBIL > 17.1 μmol/L
  5. dPatients based on abnormal liver test (Group A) and liver injury (Group B)
  6. eComplication liver dysfunction included 44 non-severe and 62 severe patients